Objective: To determine the possible therapeutic gain of using three-dimensional conformal radiotherapy (3D-CRT) as a treatment option for portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC) and to evaluate the tolerance and toxicity of using such treatment. Materials and methods: Sixty two patients were enrolled in this prospective study between June 2013 and August 2015. The clinical target volume (CTV) was the PVTT and the prescribed dose was 50 Gy/25 fractions. The median follow-up time was 7.4 months. Results: The thrombus crude response rate was 40.4% and the only significant prognostic factor for response was the thrombus size. Responders had significant better survival compared to non-responders with a median survival of 12.5 and 8 months respectively (P < 0.0001). The radiation toxicity profile was satisfactory. Conclusions: The results of this study suggest that radiotherapy should be considered as a safe treatment option for HCC patients with PVTT. It is effective not only for PVTT local control but also for survival, although prospective randomized trials are needed to confirm these results.
Introduction
Hepatocellular carcinoma accounts for about 80% -90% of primary liver cancers. Worldwide it is ranked as the fifth most common cancer and the third most common cause of cancer mortality [1] . Eighty-five percent of cases occur in the developing countries [2] . In Egypt, HCC contributes about 8% of all cancers and it is ranked as second most common cancer in males and sixth in females [3] .
Vascular invasion (especially invasion of the portal vein) is often noticed in patients with advanced HCC. The prognosis of patients with HCC is generally poor, but when accompanied by portal vein tumor thrombus, a median survival of 2.7 -4.0 months was reported if left untreated [4] .
Treatment strategies for HCC vary throughout the world. There is still no universal accepted form of treatment for HCC with PVTT and most of the guidelines encourage investigating new agents within clinical trials. According to Barcelona Clinic Liver Cancer (BCLC) guidelines patients with advanced stage disease are complicated by portal invasion but status with good performance are candidates for new antitumor agents [5] . The role of external beam radiotherapy in the treatment of HCC had been limited due to the risk of developing radiation-induced liver disease (RILD) [6] . With technological advances in radiation therapy, it became possible to deliver a higher dose of radiation while sparing healthy tissue from excessive irradiation. Recently, many retrospective and few phase 2 studies have shown that 3D-CRT is effective not only for tumor response but also for survival in HCC patients with PVTT. Median survival time of those patients was reported from 6 to 13 months [7] [8] [9] .
Based on this background, this study was conducted to determine the possible therapeutic gain of using 3-DCRT as a treatment option for PVTT and to evaluate the tolerance and toxicity of using such treatment. The study also evaluated the thrombus response to radiotherapy and tried to define the prognostic factors related to both the patient and the thrombus.
Materials and Methods

Patients
Sixty two patients with hepatocellular carcinoma and portalvein tumor throm- PVTT presence and its location were documented from the most recent imaging before treatment using the following criteria: 1) a low-attenuation intraluminal filling defect on portal phase; 2) an enhanced inner side of the filling defect on the arterial phase.
Institutional review board (IRB) approval was acquired as the study poses no harm on the participants. An informed consent was obtained from all the participants after explaining the purpose of the study, and they were informed that all the data will be presented anonymously.
Radiation Therapy Treatment
During the CT simulation the patients were scanned in the supine position with both arms raised above the head, both arterial and portal venous phase CT scans were performed. Slice thickness was 2.5 mm. The patient was advised and trained to perform shallow respiration during the scan. A reference point was marked on the skin at the level of the xiphoid process with 3 radio opaque markers applied during the scan and their corresponding sites were tattooed. A daily fraction of 2 Gy was prescribed to deliver a total dose of 50 Gy over 5 weeks. The treatment was prescribed at 5 fractions per week using a multi-energy linear accelerator after confirming the isocenter position using electronic portal imaging. The planned treatment schedule was designed to be kept as strict as possible. In case of treatment interruption, the missing treatment was compensated on weekends.
Treatment Evaluation and Follow up
During treatment the patients were monitored weekly by physical examination, complete blood cell count, liver function tests and bleeding profile. Patient's position during treatment was verified by weekly electronic portal imaging. Muliphasic CT, Liver function test, bleeding profile and AFP were done 4 -6 weeks after the completion of the radiation course, and every 3 months thereafter. Full PVTT response was evaluated by determining the maximum reduction rate within 6 months after the end of radiotherapy. The response of the PVTT to treatment was assessed based on the "Response Evaluation Criteria in Solid Tumors (RECIST)" [10] . Treatment related toxicities were assessed using the Radi- 
Statistical Analysis
Correlation between PVTT response and other variables was evaluated using the chi-square test or Fisher's exact test. Overall survival was estimated using the Kaplan-Meier method. Overall survival was measured from the date of diagnosis to the date of death or last follow up date. For univariate survival analyses, the log-rank test was used to evaluate differences. Potential prognostic variables that showed statistical significance in univariate analysis were used to perform multivariate analysis with the Cox proportional hazards model. All statistical analysis was performed using SPSS version 20.0. P-value < 0.05 was considered statistically significant.
Results
Sixty two patients with hepatocellular carcinoma and portal vein tumor thrombus who met the inclusion criteria were enrolled in this prospective study between June 2013 and August 2015. Patient characteristics were summarized at Table 1 .
Most of the patients were diagnosed in their sixth decade. Their age ranged between 43 and 75 years. The mean age was 61 years and male to female ratio was 9:1.Most of the patients had liver function of Child-Pugh class A. Only 18% of the patients had Child-Pugh class B. Forty three patients were +ve for HCV while only 5 patients were +ve for HBV. Fourteen patients had no prior history of viral hepatitis. Patients were classified into 2 groups according to their serum AFP level with a cutoff value of 400 ng/ml. Eighty five percent of the patients and 59.6% respectively. In regards of local response, multiple potential predictors were analyzed and the only significant one was the PVTT size ( Table 2 ).
Thrombi of a maximum diameter of 3 cm or less had significant better local response compared to those with maximum diameter greater than 3 cm.
None of the 47 patients who were evaluated after treatment experienced grade-3 or higher toxicities. Two patients were diagnosed by grade-2 liver toxicity and only 1 patient complained of grade-2 GIT toxicity. All the patients were followed up for at least 1 year or till death. The median follow up time was 7.4 months ( Table 3 ). The median overall survival (OS) of all the patients in the study was 8.2 months. The 1-year and 2-year OS were 25.2% and 1.9% respectively (Figure 2 ). The PVTT response was the most significant prognostic factor by both univariate and multivariate analyses in terms of OS.
Responders had significant better survival compared to non-responders with a median survival of 12.5 and 8 months respectively (P < 0.0001) (Figure 3 primary tumor was included in the target volume for some patients and excluded for others. In our study, we defined the clinical target volume as the PVTT and excluded the primary liver tumor for proper assessment of the thrombus response to radiotherapy. Conventional fractionation of 50 Gy over 25 treatment fractions was prescribed to all the patients in this study. This dose was prescribed based on the earlier results by Haung et al. and Hou et al. when they reported significant lower survival for patients who were treated with RT doses lower than 50 Gy compared to those who received 50 Gy or higher [8] [12] .
In this study, 17.7% of the patients were not able to complete the radiotherapy course. Moreover, 4 out of 51 patients who completed the protocol did not have post-treatment evaluation because they died before the scheduled follow-up date. Huang et al. also categorized 48% of their patients as "missing status" [8] . In a similar study conducted by Lin et al, 29 out of 43 patients received incomplete radiotherapy and died before evaluation [7] .
The response of the PVTT was evaluated in multiple recent retrospective trials, the complete and partial response rates were reported from 5.8% to 20.8% and from 19.4% to 55.6% respectively [8] [12] [13] . The reason for this wide range is the discrepancy is the previous trials design. As mentioned before, most of the trials were retrospective and included patients who were treated with different radiation doses, unclear definition of target volume and different radiotherapy techniques including 2D, 3D-CRT, IMRT, SBRT and proton therapy. The results of these trials are comparable with our results, the complete and partial response rates were 8.5% and 31.9% respectively. After analyzing the potential predictors for PVTT response, the only significant factor was the thrombus size. PVTT of maximum diameter of 3 cm or less had significant better response rate compared to those of maximum diameter larger than 3 cm (P = 0.006). These results confirm the results published by Toya et al on 2007 when they defined portal vein tumor thrombi of 3 cm maximum diameter or less as a favorable factor for local response [14] .
The median survival for all the patients in our study was 8.3 months. The 1year OS and 2 years OS rates were 25.2% and 1.9% respectively. Multiple predictors of survival were identified in this study. The PVTT response was the most significant prognostic factor by both univariate and multivariate analyses in terms of OS. Responders had significant better survival compared to nonresponders with a median survival of 12.5 and 8 months respectively. These results are confirming the results published earlier by Kim et al when they found a significant correlation between PVTT response and survival. The median survival which was reported in their study was 15 months for responders and 8 months for non-responders [15] . In this study, performance status as a predictor of survival was found to be statistically significant by both univariate and multivariate analyses. Similar results were published on 2012 by Rim et al. when they correlated between poor performance status and worse survival outcomes [13] .
By univariate analysis, patients with Child-Pugh liver function class A had significant better survival compared to those with class B. By multivariate analysis, the difference was not statistically significant. The same was observed with lower serum AFP level, patients with AFP level below 400 ng/ml had better survival but that was only significant with univariate analysis. Our results are supporting the results of the previous trials that considered radiotherapy as a safe treatment for HCC with PVTT.
During post-treatment follow up, most of our patients claimed a significant improvement of their initially symptoms (mainly abdominal pain) but unfortunately our study was not designed to assess the subjective improvement of the symptoms (Table 4 ).
Conclusion
The results of this study suggest that radiotherapy should be considered as a safe treatment option for HCC patients with PVTT. It is effective not only for PVTT local control but also for survival, although prospective randomized trials are needed to confirm these results.
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